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THE EFFECT OF A LETTER-BASED
EDUCATIONAL PROGRAM FOR PRESCRIBERS
AND PHARMACISTS ON ADHERENCE TO
NATIONAL ASTHMA GUIDELINES AND
HEALTHCARE UTILIZATION
Coleman CI1, Reddy P2, Laster-Bradley NM3, Dorval S4,
White CM1
1University of Connecticut, Storrs, CT, USA; 2Abt Associates
Clinical Trials, Cambridge, MA, USA; 3ACS State Healthcare,
Atlanta, GA, USA; 4Department of Social Services, Hartford,
CT, USA
OBJECTIVE: To assess the effect of a letter-based inter-
vention program, targeted at prescribers and pharmacists,
on adherence to national guidelines and healthcare uti-
lization in the Connecticut asthma Medicaid population.
METHODS: A retrospective DUR was conducted from
April to June 2001. Patients with asthma in the Con-
necticut Medicaid Program submitting >1 claim per
month (over a 6-month period) for short-acting b2-
agonists were identiﬁed (intervention group; n = 135).
Patient speciﬁc intervention packets explaining the
problem, the patient’s medication proﬁle, an asthma edu-
cation leaﬂet, response form and return envelope were
mailed to the patients’ prescribers and pharmacists. A
control group of asthma patients, who were not HDB
users at baseline and drawn from the same Medicaid
program, were also identiﬁed (n = 510). Utilization of
long-term asthma control agents and spacers and health-
care utilization were compared between the intervention
and control patients 6 months after the mailing.
RESULTS: At baseline, the intervention group had lower
utilization of long-term control agents compared to the
control group (58% vs. 96%, respectively; p < 0.001) but
there was no difference after the intervention program
(65% vs. 71%, p = 0.169). A greater number of claims
were submitted for spacers in the intervention group com-
pared to control after the mailing (7% vs. 2%, p = 0.007).
Before the mailing, the intervention group incurred more
prescriber ofﬁce visits than the control group (mean ± SD;
0.46 ± 0.82 vs. 0.25 ± 0.66, p < 0.001) but this differ-
ence was not evident after the intervention program (0.24
± 0.63 vs. 0.18 ± 0.60, p = 0.283). CONCLUSION: This
intervention program had a modest impact on improving
the use of long-term control agents and reducing pre-
scriber ofﬁce visits.
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Verbrugge RR, Sokol M, McGuigan K
Medco Health Solutions, Inc, Franklin Lakes, NJ, USA
OBJECTIVES: National treatment guidelines recommend
daily use of controller medications for people with per-
sistent asthma. Consistent use of controllers can help
reduce medical resource utilization, but compliance with
therapy is often poor. Our objective is to quantify the
compliance gap and the opportunity cost of current
asthma treatment in a large beneﬁt plan population.
METHODS: Asthma patients were participants in
medical and drug beneﬁt plans sponsored by a large
national employer. All were under age 65 and had con-
tinuous beneﬁt eligibility during the study period, June
1997 through May 1999. They were identiﬁed based on
medical claims for asthma-related services. During a 12-
month analysis period, medical claims and prescription
drug claims were used to track utilization. Medication
compliance was deﬁned by the percentage of days during
the analysis period that a patient had days-supply of 
a prescribed drug class; less than 80% was considered
noncompliant. Cost and utilization were modeled using
regression analysis, adjusting for age, sex, comorbidity,
disease severity, and plan type. RESULTS: Only 9.9% of
asthma patients were compliant with their prescribed
controller medications. Low compliance was common;
41.2% of patients had less than a 20% days-supply of
controller medications during the analysis period. For
quick-relief medications, the patient distribution was
skewed toward high utilization. High levels of compliance
with controller medications were found to decrease hos-
pitalization risk by 36% (comparing the highest levels 
of compliance). High compliance with controllers also
reduced asthma-related medical costs, more than offset-
ting the increase in drug costs. The return-on-investment
(ROI) for this guidelines-based increase in drug utiliza-
tion was 2 :1. CONCLUSIONS: Therapy for many
asthma patients is suboptimal, including under use of
controller medications and overuse of quick-relief med-
ications. Shifting patient utilization toward daily con-
troller use can reduce hospitalization risk and decrease
overall healthcare costs.
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COMPARISON OF RISK FOR HOSPITAL AND/OR
EMERGENCY DEPARTMENT VISITS FOR
MEDICAID PATIENTS WITH COPD
Rascati KL1, Stanford RH2, Borker RD2
1University of Texas, Austin,TX, USA; 2GlaxoSmithKline,
Research Triangle Park, NC, USA
OBJECTIVES: To compare the risk of hospital and/or
Emergency Department (ED) visits [events], based on
various treatment regimens in a population of Medicaid
patients with Chronic Obstructive Pulmonary Disease
(COPD). METHODS: Retrospective observational
cohort design. Texas Medicaid patients aged 40 to 65
years enrolled from 1998 to 2001 with a primary diag-
nosis of COPD were identiﬁed. Five index therapy
cohorts were assessed: 1) ipratropium / Combivent (IPR);
2) salmeterol (SAL); 3) inhaled corticosteroid (ICS); 4)
ICS + IPR; and 5) ICS + SAL. Subjects were followed until
they had a COPD-related event, or for 12-months,
whichever came ﬁrst. Cox proportional hazard analysis
compared therapy cohorts, assessing time to ﬁrst COP-
